89 related articles for article (PubMed ID: 18701419)
1. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
2. Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies.
Chiasakul T; Mullier F; Lecompte T; Nguyen P; Cuker A
Semin Nephrol; 2023 Nov; 43(6):151477. PubMed ID: 38290962
[TBL] [Abstract][Full Text] [Related]
3. Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components.
Siddiqui F; Hoppensteadt D; Bontekoe E; Farooqui A; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620954913. PubMed ID: 33030036
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.
Zhou X; Li L; Linhardt RJ; Liu J
FEBS J; 2013 May; 280(10):2523-32. PubMed ID: 23374371
[TBL] [Abstract][Full Text] [Related]
5. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
[TBL] [Abstract][Full Text] [Related]
6. Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study.
Sedghi A; Heubner L; Klimova A; Tiebel O; Pietsch J; Mirus M; Barlinn K; Minx T; Beyer-Westendorf J; Puetz V; Spieth P; Siepmann T
Thromb Haemost; 2022 Nov; 122(11):1954-1962. PubMed ID: 35672013
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Enoxaparin during Hemodialysis Covered by Regional Citrate Anticoagulation in Acute Kidney Injury: A Prospective Cohort Study.
Wiegele M; Adelmann D; Dibiasi C; Pausch A; Baierl A; Schaden E
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640507
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell J; Noveck RJ; Shi M
Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of direct anticoagulants.
Lison S; Spannagl M
Wien Med Wochenschr; 2011 Feb; 161(3-4):58-62. PubMed ID: 21404140
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
12. From heparins to factor Xa inhibitors and beyond.
Alban S
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
[TBL] [Abstract][Full Text] [Related]
13. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
14. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
15. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
16. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
